ANNOUNCED ONGOING Drug recall · Reported 20 Nov 2026 · FDA company announcement, classification pending
Breckenridge Propranolol Hydrochloride Extended-Release recalled
Breckenridge Pharmaceutical is recalling Breckenridge Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg, distributed nationwide in the US. The recall was initiated on 16 Nov 2026 and is listed as ongoing.
Recall details
- Recall number
- FDA-PR-ba9cad1bc680
- Recalling firm
- Breckenridge Pharmaceutical
- Brand
- Breckenridge
- Classification
- Pending
- Status
- Ongoing
- Recall initiated
- 16 Nov 2026
- Reported
- 20 Nov 2026
- Reason category
- Foreign Material
- Drug class
- Blood Pressure Medication
Timeline
| 16 Nov 2026 | Recall initiated by company | |
| 20 Nov 2026 | Published in enforcement report | +4 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Due to potential metal contamination. November 16, 2026— Breckenridge Pharmaceutical, Inc. (Breckenridge) is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination. Risk Statement Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market. To date, Breckenridge is not aware of any adverse events assessed to be related to this recall. Product from the affected lot subject to this recall was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 04, 2026. Recalled Product Product Package Size NDC Lot Number Expiration Date Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg 100-count bottle 51991-817-01 PK25110035 May 2029 What Consumers Should Do Consumers should immediately stop taking product from the lot subject to this recall and contact their physician or healthcare provider for medical advice and replacement instructions. Consumers should return any unused portion of the affected product to the pharmacy where it was obtained. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Wholesa
Foreign material recalls cover pieces of metal, plastic, glass, wood or other objects that got into the product during processing and could cause injury if eaten.
Product as listed by the company
Breckenridge Propranolol Hydrochloride Extended-Release Capsules, USP, 60mg
Where it was distributed
Nationwide
Questions about this recall
Why was it recalled?
Due to potential metal contamination. November 16, 2026— Breckenridge Pharmaceutical, Inc. (Breckenridge) is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination. Risk Statement Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market. To date, Breckenridge is not aware of any adverse events assessed to be related to this recall. Product from the affected lot subject to this recall was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 04, 2026. Recalled Product Product Package Size NDC Lot Number Expiration Date Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg 100-count bottle 51991-817-01 PK25110035 May 2029 What Consumers Should Do Consumers should immediately stop taking product from the lot subject to this recall and contact their physician or healthcare provider for medical advice and replacement instructions. Consumers should return any unused portion of the affected product to the pharmacy where it was obtained. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product. Wholesa
Where was it sold?
Nationwide
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does an unclassified recall mean?
The FDA assigns a class once it has assessed the health risk. Until then the recall is listed without one.
Read the official FDA notice · Source record retrieved 20 Nov 2026. This is a company announcement published by the FDA; the FDA has not yet classified the recall. The record is updated when the classification appears in the Enforcement Report. This page reports the record and gives no medical advice.
More recalls from Breckenridge Pharmaceutical
All 36| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 30mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 60mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules USP, 60mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 60 mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |
| Drug | CLASS II | Duloxetine Delayed-Release Capsules, USP, 60 mg recalledDuloxetine | Breckenridge Pharmaceutical | Nitrosamine Impurity | Nationwide |